<20 G Units Negative
=>20 G Units Positive - Risk factor for thrombosis and pregnancy loss
20 M Units Negative
=>20 M Units Positive - Risk factor for thrombosis and pregnancy loss
|CPT Code||0030T (x2)
|Schedule Turnaround Time||Assay performed weekly. Report availability is within one week from the time
of specimen receipt.
|Specimen Requirements||Specimen need not be refrigerated or frozen. Collect 5-10 ml of blood in a red top
or serum separator tube. If possible, separate serum from clot and place into orange tube provided with
IMMCO collection kits. Do not puncture top of orange tube. If separation facilities are not available, the
blood can be sent in the tube used for collection.
|Sample Stability||Sample is stable at ambient temperature during shipment. If sample is stored prior to
shipment, it is stable refrigerated (2-8°C) up to five days and frozen (-20°C or lower) up to one year.
|Clinical Relevance||Anti-phospholipid (aPL) antibodies have been associated with venous and arterial thrombosis as well as with
recurrent fetal loss. Patients with these symptoms and high aPL antibody levels have been diagnosed as
having the anti-phospholipid antibody syndrome (APS). Anti-phospholipid syndrome can occur in patients
with systemic lupus erythematosus (SLE) or other autoimmune diseases (secondary anti-phospholipid
syndrome) or in patients without underlying autoimmune disease (primary anti-phospholipid syndrome).
In clinical practice anti-cardiolipin antibodies detected by ELISA is one of the most established and
standardised tests for diagnosis of the antiphospholipid syndrome. However, the family of aPL antibodies has
recently expanded to include a heterogeneous group of
antibodies whose specificity is directed against phospholipid binding proteins or their complex with
- Anti-Phospholipid/Cardiolipin Antibodies (APL)
- Antiphospholipid Syndrome
- Cardiovascular Disease
- Systemic Lupus Erythematosus (SLE)